The rationale for this choice is that the oral hypoglycemic drug metformin is efficacious for the treatment of obesity consequent to type 2 diabetes [94], and that the principal targets of metformin include the liver (insulin functional agonism) [95] and the brain (reduction of NPY orexigenic signals) [96]. Here, NPY is linked to Obesity.